[go: up one dir, main page]

WO2013171729A3 - Composés d'aryl- et hétéroarylamide en tant que modulateur de rorγt - Google Patents

Composés d'aryl- et hétéroarylamide en tant que modulateur de rorγt Download PDF

Info

Publication number
WO2013171729A3
WO2013171729A3 PCT/IB2013/058108 IB2013058108W WO2013171729A3 WO 2013171729 A3 WO2013171729 A3 WO 2013171729A3 IB 2013058108 W IB2013058108 W IB 2013058108W WO 2013171729 A3 WO2013171729 A3 WO 2013171729A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulator
ror
aryl
amide compounds
ror gamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/058108
Other languages
English (en)
Other versions
WO2013171729A2 (fr
Inventor
Sachin Sundarlal Chaudhari
Abraham Thomas
Neelima Khairatkar-Joshi
Malini Bajpai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ichnos Sciences SA
Original Assignee
Glenmark Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals SA filed Critical Glenmark Pharmaceuticals SA
Publication of WO2013171729A2 publication Critical patent/WO2013171729A2/fr
Publication of WO2013171729A3 publication Critical patent/WO2013171729A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des composés de formule (I), et des sels pharmaceutiquement acceptables de ceux-ci, en tant que modulateur de récepteur gamma orphelin associé au rétinoïde t (RORϒt). Ces composés préviennent, inhibent, ou suppriment l'action de RORϒt et sont donc utiles dans le traitement d'une maladie, d'un trouble, d'un syndrome ou d'une affection médiés par RORϒt tels que la douleur, l'inflammation, la BPCO, l'asthme, la polyarthrite rhumatoïde, la colite, la sclérose en plaques, des maladies neurodégénératives ou le cancer.
PCT/IB2013/058108 2013-01-08 2013-08-29 Composés d'aryl- et hétéroarylamide en tant que modulateur de rorγt Ceased WO2013171729A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN55/MUM/2013 2013-01-08
IN55MU2013 2013-01-08
US201361760301P 2013-02-04 2013-02-04
US61/760,301 2013-02-04
IN811MU2013 2013-03-19
IN811/MUM/2013 2013-03-19

Publications (2)

Publication Number Publication Date
WO2013171729A2 WO2013171729A2 (fr) 2013-11-21
WO2013171729A3 true WO2013171729A3 (fr) 2014-02-06

Family

ID=49584403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/058108 Ceased WO2013171729A2 (fr) 2013-01-08 2013-08-29 Composés d'aryl- et hétéroarylamide en tant que modulateur de rorγt

Country Status (1)

Country Link
WO (1) WO2013171729A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2727191C2 (ru) * 2015-06-05 2020-07-21 Лид Фарма Холдинг Б.В. МОДУЛЯТОРЫ ROR ГАММА(RORγ)
RU2727698C2 (ru) * 2015-06-05 2020-07-23 Лид Фарма Холдинг Б.В. МОДУЛЯТОРЫ ROR ГАММА (RORγ)
US11299456B2 (en) * 2016-12-05 2022-04-12 Lead Pharma Holding B.V. ROR gamma (RORγ) modulators

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150092244A (ko) 2012-12-06 2015-08-12 글락소 그룹 리미티드 자가면역 및 염증성 질환의 치료에 사용하기 위한 레티노이드-관련 고아 수용체 감마 (ror-감마)의 조절제
HRP20181291T1 (hr) * 2013-08-02 2018-10-19 Pfizer Inc. Heterobicikloarilni inhibitori rorc2 i njihova upotreba
WO2015052675A1 (fr) * 2013-10-10 2015-04-16 Glenmark Pharmaceuticals S.A. Utilisation de composés substitués dihydro-benzimidazole comme modulateurs du ror gamma
EA030393B1 (ru) 2013-12-05 2018-07-31 ЛИД ФАРМА СЕЛ МОДЕЛЗ АйПи Б.В. МОДУЛЯТОРЫ ROR ГАММА (RORγ)
TW201605797A (zh) 2013-12-10 2016-02-16 葛蘭馬克製藥公司 作為ror伽馬調節物的雙環雜芳基化合物
LT3102576T (lt) 2014-02-03 2019-08-12 Vitae Pharmaceuticals, Llc Ror-gama dihidropirolopiridino inhibitoriai
CN104926733B (zh) * 2014-03-18 2019-05-10 北京韩美药品有限公司 作为RORγ调节剂的化合物
NZ724602A (en) * 2014-03-27 2022-12-23 Piramal Entpr Ltd Ror-gamma modulators and uses thereof
AP2016009542A0 (en) 2014-04-16 2016-11-30 Glenmark Pharmaceuticals Sa Aryl and heteroaryl ether compounds as ror gamma modulators
KR20170012388A (ko) 2014-05-28 2017-02-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 신규 화합물
CR20160549A (es) 2014-05-28 2017-04-28 Glaxosmithkline Ip Dev Ltd COMPUESTOS DERIVADOS DE N-(3-((4-(TETRAHIDROFURANO/TETRAHIDROPIRANO-3-CARBONIL)PIPERAZIN-1-IL) METIL)FENIL)FORMAMIDA ACTIVOS COMO MODULADORES DEL RECEPTOR HUÉRFANO GAMMA (RORy) RELACIONADOS CON RETINOIDES.
ES2710487T3 (es) 2014-05-28 2019-04-25 Glaxosmithkline Ip Dev Ltd Derivados de piperazina como moduladores de ror-gamma
MA40759A (fr) 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
EA031967B1 (ru) 2014-10-14 2019-03-29 Вайтаи Фармасьютиклз, Инк. ДИГИДРОПИРРОЛОПИРИДИНОВЫЕ ИНГИБИТОРЫ ROR-γ
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
TW201625588A (zh) * 2014-11-05 2016-07-16 第一三共股份有限公司 環狀胺衍生物
EP3268087A4 (fr) 2015-03-12 2018-08-29 The Regents of the University of California Méthodes de traitement du cancer par des inhibiteurs de ror gamma
SMT202100286T1 (it) 2015-05-15 2021-07-12 Aurigene Discovery Tech Ltd Composti di tetraidrochinolinone sostituito come modulatori ror-gamma
WO2016193894A1 (fr) 2015-05-29 2016-12-08 Glenmark Pharmaceuticals S.A. Traitement de troubles respiratoires au moyen d'inhibiteurs ror-gamma
EP3101007A1 (fr) * 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Modulateurs de gamma ror (rory)
EP3101009A1 (fr) * 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Modulateurs de gamma ror (rory)
WO2017021879A1 (fr) * 2015-08-03 2017-02-09 Glenmark Pharmaceuticals S.A. Nouveaux composés utilisés en tant que modulateurs de ror gamma
DK3331876T3 (da) 2015-08-05 2021-01-11 Vitae Pharmaceuticals Llc Modulators of ror-gamma
JP2018526372A (ja) * 2015-08-28 2018-09-13 グレンマーク・ファーマシューティカルズ・エスエー Ｒｏｒガンマ調節剤としての新規の炭素環化合物
RU2760373C2 (ru) 2015-09-18 2021-11-24 Какен Фармасьютикал Ко., Лтд. Биарильное производное и содержащее его лекарственное средство
WO2017051319A1 (fr) * 2015-09-21 2017-03-30 Glenmark Pharmaceuticals S.A. Composés éther d'aryle et éther d'hétéroaryle en tant que modulateurs de ror gamma
MX385332B (es) 2015-11-20 2025-03-18 Vitae Pharmaceuticals Llc Moduladores de ror-gamma.
JP6448867B2 (ja) 2015-12-15 2019-01-09 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ イソインドール化合物
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
WO2017199103A1 (fr) * 2016-05-18 2017-11-23 Glenmark Pharmaceuticals S.A. Composés de benzamide comme modulateurs gamma ror
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
AR109042A1 (es) 2016-07-14 2018-10-24 Cadila Healthcare Ltd COMPUESTOS MODULARES DE RORg
TW201811760A (zh) 2016-07-14 2018-04-01 印度商卡迪拉保健有限公司 新穎的環丙基衍生物
US10954215B2 (en) 2016-12-13 2021-03-23 Boehringer Ingelheim International Gmbh Compounds as modulators of ROR gamma
WO2018116285A1 (fr) 2016-12-23 2018-06-28 Glenmark Pharmaceuticals S.A. Dérivés de morpholine substitués en tant que modulateurs de ror gamma
WO2018145653A1 (fr) * 2017-02-09 2018-08-16 复旦大学 Composé biaryle, procédé de préparation et utilisation associés
CN108863850B (zh) * 2017-02-09 2021-05-18 复旦大学 联芳基类化合物及其制备方法和用途
WO2018185675A1 (fr) 2017-04-04 2018-10-11 Glenmark Pharmaceuticals S.A. Analogues d'oxoazétidine substitués en tant que modulateurs de ror gamma
US11034654B2 (en) 2017-06-14 2021-06-15 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ROR-gamma modulators
WO2019018975A1 (fr) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibiteurs de ror gamma
UA126583C2 (uk) 2017-07-24 2022-11-02 Вітае Фармасьютікалс, Ллс ІНГІБІТОРИ ROR<font face="Symbol">g</font>
SMT202200134T1 (it) 2018-03-08 2022-05-12 Incyte Corp Composti di amminopirazindiolo come inibitori di pi3k-y
US10975057B2 (en) 2018-06-18 2021-04-13 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of RORgT
JP2021527660A (ja) 2018-06-18 2021-10-14 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγｔのモジュレータとしてのフェニル及びピリジニル置換イミダゾール
EP3790865A1 (fr) 2018-06-18 2021-03-17 Janssen Pharmaceutica NV Pyrazoles substitués par phényle utilisés en tant que modulateurs de roryt
WO2019244002A1 (fr) * 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Pyridinyl-pyrazoles utilisés utilisés comme modulateurs de roryt
WO2020010003A1 (fr) 2018-07-02 2020-01-09 Incyte Corporation DÉRIVÉS D'AMINOPYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K-γ
TW202146381A (zh) * 2020-05-15 2021-12-16 大陸商上海輝启生物醫藥科技有限公司 可用作RORγ調節劑的聯芳基類化合物
WO2023146513A1 (fr) * 2022-01-25 2023-08-03 Vivace Therapeutics, Inc. Composés et leurs procédés d'utilisation
CN116715613A (zh) * 2023-05-09 2023-09-08 中山大学 一种RORγ共价抑制化合物及其制备方法与应用
WO2025141891A1 (fr) * 2023-12-29 2025-07-03 キッセイ薬品工業株式会社 Composé biaryle

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012100734A1 (fr) * 2011-01-24 2012-08-02 Glaxo Group Limited Composés utiles en tant que modulateurs du récepteur apparenté au récepteur des rétinoïdes gamma
WO2012100732A1 (fr) * 2011-01-24 2012-08-02 Glaxo Group Limited Modulateurs des récepteurs orphelins gamma apparentés au récepteur des rétinoïdes, composition les contenant et utilisations associées

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012028100A1 (fr) 2010-09-01 2012-03-08 Glaxo Group Limited Nouveaux composés
WO2012027965A1 (fr) 2010-09-01 2012-03-08 Glaxo Group Limited Nouveaux composés
US9512111B2 (en) 2010-11-08 2016-12-06 Lycera Corporation N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
EP2511263A1 (fr) 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Composés de pyrrolo sulfonamide pour la modulation d'activité de récepteur-gamma orphelin (gamme ROR, NR1F3) associée au RAR de récepteur nucléaire orphelin et pour le traitement des maladies inflammatoires et de maladies auto-immunes chroniques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012100734A1 (fr) * 2011-01-24 2012-08-02 Glaxo Group Limited Composés utiles en tant que modulateurs du récepteur apparenté au récepteur des rétinoïdes gamma
WO2012100732A1 (fr) * 2011-01-24 2012-08-02 Glaxo Group Limited Modulateurs des récepteurs orphelins gamma apparentés au récepteur des rétinoïdes, composition les contenant et utilisations associées

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2727191C2 (ru) * 2015-06-05 2020-07-21 Лид Фарма Холдинг Б.В. МОДУЛЯТОРЫ ROR ГАММА(RORγ)
RU2727698C2 (ru) * 2015-06-05 2020-07-23 Лид Фарма Холдинг Б.В. МОДУЛЯТОРЫ ROR ГАММА (RORγ)
US11299456B2 (en) * 2016-12-05 2022-04-12 Lead Pharma Holding B.V. ROR gamma (RORγ) modulators

Also Published As

Publication number Publication date
WO2013171729A2 (fr) 2013-11-21

Similar Documents

Publication Publication Date Title
WO2013171729A3 (fr) Composés d&#39;aryl- et hétéroarylamide en tant que modulateur de rorγt
PH12016502045A1 (en) Aryl and heteroaryl ether compounds as ror gamma modulators
PH12016501105A1 (en) Bicyclic heteroaryl indole analogues useful as ror gamma modulators
MY198809A (en) Novel compounds as ror gamma modulators
WO2017087608A8 (fr) Modulateurs de ror-gamma
PH12016501972B1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
WO2015010078A3 (fr) Composés hétéroaryles bicycliques substitués condensés en 6,5
MY196749A (en) Eif4a-inhibiting compounds and methods related thereto
MY174188A (en) Heterocyclyl compounds
HK1201819A1 (en) Novel compounds
WO2014179564A8 (fr) Inhibiteurs du ror-gamma à base de thiazolopyrrolidine
MX383592B (es) Moduladores de ror gamma (ror?).
PH12018501237A1 (en) Isoindole compounds
NZ702239A (en) Heteroaryl compounds and methods of use thereof
PH12018500411A1 (en) Novel carbocyclic compounds as ror gamma modulators
MX2015015741A (es) Derivados de n-(heteroaril)-sulfonamida utiles como inhibidores de s100.
EA201991373A1 (ru) МОДУЛЯТОРЫ ROR ГАММА (RORγ)
WO2015031198A3 (fr) Compositions pharmaceutiques de bendamustine
PH12016501215A1 (en) Azaindole derivative
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
WO2015181837A3 (fr) Nouveaux composés utilisés comme agents anti-tuberculeux
TH157696A (th) ตัวคุมของตัวรับที่ยังไม่ได้ระบุจำแนกประเภทที่เกี่ยวข้องกับเรตินอยด์ชนิดแกมมา (ror-แกมมา) สำหรับใช้ในการรักษาโรคทางภูมิต้านตนเองและโรคที่มีอาการอักเสบ
HK1228393A1 (en) Trifluoromethyl pyrazolyl guanidine f1fo-atpase inhibitors and therapeutic uses thereof
HK1244711A1 (zh) Hmgb1介導的炎症的治療
HK1233185A1 (en) Pharmaceutical compositions of therapeutically active compounds

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13767121

Country of ref document: EP

Kind code of ref document: A2